浙江醫藥(600216.SH)向武漢重點疫區捐獻第二批310萬元的蘋果酸奈諾沙星膠囊
格隆匯2月2日丨浙江醫藥(600216.SH)公佈,近期,湖北省武漢市等多個地區發生新型冠狀病毒感染的肺炎疫情。公司結合生產經營實際,積極履行社會責任,支持疫情防控工作。2020年1月26日,公司通過浙江省紅十字會,向湖北、浙江疫區捐獻第一批價值200萬元的抗感染藥物蘋果酸奈諾沙星膠囊(商品名:太捷信,一類新藥)和善款100萬元人民幣。
1月27日晚,公司又通過浙江省紅十字會向武漢重點疫區捐獻第二批價值310萬元的蘋果酸奈諾沙星膠囊。截至目前,公司為本次抗疫共捐獻價值510萬元的藥品和100萬元善款。
本次捐贈的蘋果酸奈諾沙星膠囊是公司研發的於2016年上市的一類新藥,2019年經過國家談判進入國家醫保目錄。本品適用於治療對奈諾沙星敏感的由肺炎球菌、金黃色葡萄球菌、流感嗜血桿菌、副流感嗜血桿菌、卡他莫拉菌、肺炎克雷伯菌以及肺炎支原體、肺炎衣原體和嗜肺軍團菌所致的輕、中度成人(≥18歲)社區獲得性肺炎。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.